Osimertinib Mesylate

甲磺酸奥希替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameOsimertinib Mesylate
Drug Alias Name奥斯替尼Mereletinibosimertinib奥西替尼甲磺酸奥斯替尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR L858R inhibitorsEGFR 19del inhibitors +[7] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3 +[7] 
Therapy Area/IndicationsBrain metastasesSolid tumoursNeoplasm, Residual +[36] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/13
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesThermo Fisher Scientific IncChinese University Of Hong Kong (Cuhk)Astrazeneca Pharmaceutical Co Ltd +[11] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of California San FranciscoUniversity of Texas Southwestern Medical Center +[7] 
Active IndicationsBrain metastasesSolid tumoursNeoplasm, Residual +[34] 
Inactive IndicationsMeningeal NeoplasmsNeoplasms

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG